Balentine LLC’s Genmab GMAB Stock Holding History

Balentine LLC’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-664	Closed	-$23K	–	447
2020 Q2	$23K	Buy	+664	New	+$18.1K	﹤0.01%	367
2019 Q4	–	Sell	-529	Closed	-$11K	–	656
2019 Q3	$11K	Buy	+529	New	+$10.4K	﹤0.01%	325

Other funds holding GMAB

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Balentine LLC's GMAB Position: Q3 2020 in Review

Balentine LLC sold out of Genmab (GMAB) in Q3 2020, closing a stake of 664 shares — an estimated $23K sold.

Balentine LLC first reported a position in GMAB in Q3 2019 and held it in 2 quarters. The position peaked at $23K in Q2 2020. 198 funds tracked by Wall St. Rank hold GMAB as of Q3 2020.

Balentine LLC reported no remaining Genmab position as of Q3 2020 after selling out during the quarter.
Balentine LLC sold 664 Genmab shares in Q3 2020, an estimated $23K.
Balentine LLC first reported a position in Genmab in Q3 2019 and held it in 2 quarters.
Balentine LLC's Genmab position peaked at $23K in Q2 2020.
198 funds tracked by Wall St. Rank held Genmab as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.